A pharmaceutical Compound comprising a Compound of the formula IB: ** Formula ** or a pharmaceutically acceptable salt, solvate, stereoisomer and / or ester thereof, wherein: R10a and R10b are each independently H or alkyl -C1-4； R12 is H or -CH3； R13 is - (CH2) 0-3CR17R18NR20R21, - (CH2) 0-3CR17R18NR17C (O) NR20R21, - (CH2) 1-3C (O) R22, - (CH2) 1-3S (O) 2R22 or - (CH2) 1-3-R23； R14 and R15 are each independently H, C1-4alkyl or arylalkyl； R17 and R18 are each independently H or C1-3alkyl； R19 is H, C1-4alkyl or arylalkyl； R20 and R21 are each independently H, C1-3alkyl, -C (O) R17 or -S (O) 2R17； or R20 and R21, taken together with the nitrogen atom to which they are attached, form a heterocyclyl ring d. 5. 6 unsubstituted or substituted members containing 1 -2 heteroatoms selected from the group consisting of N and O； R22 is H, C1-3alkyl, -OR19 or -NR20R21； and R23 is an unsubstituted or substituted 6-membered heterocyclyl d-ring containing 1 -2 heteroatoms selected from the group consisting of N and O； wherein said heterocyclyl ring d. 5. 6 unsubstituted or substituted members consisting of R20 and R21 and said heterocyclyl ring d. 5. 6 unsubstituted or substituted members of R23 are each independently unsubstituted or substituted with a C1-2 alkyl, a pharmaceutically acceptable carrier or excipient and atazanavir or a pharmaceutically acceptable salt, solvate or excipient thereof.Un Compuesto farmacéutico que comprende un Compuesto de la fórmula IB: **Fórmula** o una sal, un solvato, un estereoisómero y/o un éster farmacéuticamente aceptables del mismo, en el que: R10a y R10b son cada uno independientemente H o alquilo-C1-4； R12 es H o -CH3； R13 es -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O) NR20R21, -(CH2)1-3C(O)R22, -(CH2)1-3S(O)2R22 o -(CH2)1-3-R23； R14 y R15 son cada uno independientemente H, alquilo-C1-4 o arilalquilo； R17 y R18 son cada uno independientemente H o alquilo-C1-3； R19 es H, alquilo-C1-4 o arilalquilo； R20 y R21 son cada uno independient
